by Stacey Johnson | Nov 25, 2022
If manufacturing is the gatekeeper to success in the cell and gene therapy space, it’s not surprising that the topic regularly comes up when industry leaders come together to discuss the future or to tackle the challenges we face in commercializing cell and gene...
by Stacey Johnson | Sep 30, 2022
After returning from CellCAN’s 2022 Strategic Forum in Ottawa, Ontario, where Canada’s cell and gene therapy biomanufacturing community came together to share information and network, it is clear that the country’s biomanufacturing landscape is improving. As I and...
by Cal Strode | Sep 15, 2022
OmniaBio Inc., a subsidiary of CCRM, is building the largest facility of its kind in Canada, providing specialized manufacturing to the flourishing cell and gene therapy (CGT) industry. The new contract development and manufacturing organization (CDMO) will focus on...
by CCRM Australia | Aug 1, 2022
This post is by Harmanpreet Harmanpreet, who interned with CCRM Australia. The CCRM Australia Training Program seeks to facilitate training for the future workforce of the Australian regenerative medicine sector and includes an internship program that accepts...
by Stacey Johnson | Jun 10, 2022
The race to produce lab grown food marches on. So where are we in 2022? Two years ago, blogger Elisa D’Arcangelo outlined some of the practical issues associated with developing lab grown meat – namely cost, increasing production and taste. She also explained the...
Comments